Tandem Diabetes Care (NASDAQ: TNDM) The price target was raised from USD 95.00 to USD 102.00 by stock researchers at SVB Leerink in a report published on Thursday, Benzinga reports. The broker currently has a “Market Perform” rating for the medical device company’s stock. The price target of SVB Leerink indicates a potential plus of 14.81% compared to the previous closing of the company.
Several other stock analysts have also rated TNDM. Lake Street Capital raised its target price on Tandem Diabetes Care from $ 137.00 to $ 150.00 and gave the stock a “Buy” rating in a report on Thursday, February 25th. Oppenheimer reassigned a buy rating to shares of Tandem Diabetes Care in a report on Wednesday March 31st. Eventually, Zacks Investment Research downgraded Tandem Diabetes Care from a “buy” rating to a “hold” rating and set a price target of $ 101.00 for the company. in a report on Monday March 1st. Four research analysts have given the company a hold rating and nine have given it a buy rating. Tandem Diabetes Care currently has a consensus rating of “Buy” and a consensus target of $ 118.46.
TNDM opened at $ 88.84 on Thursday. Tandem Diabetes Care has a fifty-two week low of $ 75.26 and a fifty-two week high of $ 123.74. The company has a 50-day moving average of $ 89.28 and a 200-day moving average of $ 95.41. The company has a leverage ratio of 0.61, a fast rate of 4.94, and a current rate of 5.61. The company has a market cap of $ 5.56 billion, a P / E of -109.68, and a beta of 0.31.
Tandem Diabetes Care (NASDAQ: TNDM) last released its results on Wednesday May 5th. The medical device company reported earnings per share of $ 0.08 for the quarter, beating Zacks’ consensus estimate of $ 0.16 by $ 0.08. Tandem Diabetes Care had a negative net margin of 11.10% and a negative return on equity of 10.98%. Analysts from stock studies predict that Tandem Diabetes Care will achieve earnings per share of -0.35 in the current fiscal year.
(Display)
LSD and “mushroom stocks” are listed on the NASDAQ and a recent breakthrough is making top investors VERY excited about the upcoming “mushroom boom”.
In related news, director Kim D. Blickenstaff sold 200,000 shares in the company in a transaction dated Tuesday, March 16. The stock was sold at an average price of $ 87.27 for a total transaction of $ 17,454,000.00. In addition, EVP David B. Berger sold 8,646 shares in the company in a transaction that occurred on Thursday, March 11th. The stock sold at an average price of $ 90.22 for a total value of $ 780,042.12. Upon completion of the sale, the executive vice president now owns 13,212 shares in the company valued at approximately $ 1,191,986.64. The disclosure for this sale can be found here. Insiders sold 211,844 shares in the company last quarter, valued at $ 18,537,916. 6.00% of the shares are owned by insiders.
Several institutional investors recently changed their positions in TNDM. Monday A & Associates Inc. bought a new position in Tandem Diabetes Care shares for $ 31,000 in the fourth quarter. Manchester Financial Inc. increased its stake in Tandem Diabetes Care by 48.4% in the fourth quarter. Manchester Financial Inc. now owns 371 shares in the medical device company valued at $ 35,000 after purchasing an additional 121 shares last quarter. IFP Advisors Inc took a new position in shares of Tandem Diabetes Care valued at approximately $ 50,000 in the first quarter. GPS Wealth Strategies Group LLC acquired a new stake in Tandem Diabetes Care worth approximately $ 57,000 in the first quarter. Finally, US Bancorp DE increased its stake in Tandem Diabetes Care by 16.4% in the fourth quarter. US Bancorp DE now owns 795 shares in the medical device company valued at $ 76,000 after purchasing an additional 112 shares during the period. 88.60% of the shares belong to institutional investors.
Tandem Diabetes Care company profile
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and markets a variety of products for people with insulin-dependent diabetes in the United States. The company’s flagship is the t: slim X2 insulin delivery system, a pump platform that includes the t: slim X2 pump, the disposable 300-unit insulin cartridge and an infusion set.
See also: What Are Gap-Up Stocks?
This instant message alert was generated through narrative science technology and financial data from MarketBeat to give readers the fastest, most accurate coverage possible. This story has been reviewed by the editorial staff of MarketBeat prior to publication. Please send questions or comments about this story to [email protected]
Sponsored Article: What are high yield dividend stocks?
7 electric vehicle (EV) stocks ready for recovery
The electric vehicle (EV) sector in 2020 was almost as foamy as the “pandemic stocks”. It wasn’t that the EV sector was dormant during the Trump administration.
But as the saying goes, choices have consequences. And Wall Street knows they can make money in any administration. And as a bet that Joe Biden would win the presidency, electric vehicle stocks soared.
For starters, the Biden government has already announced that it will prioritize climate change in a way that no government has ever done. And one way to do that is to incentivize the production and purchase of electric vehicles.
And to take advantage of this shift towards electric vehicle inventories, many private companies are racing to get involved in the action. Many of these companies preferred to go public through a Special Purpose Acquisition Company (SPAC). A SPAC is basically an abbreviation to the traditional IPO process.
However, what is often going up and down, and EV stocks have been hurt since late February. However, this creates an opportunity as the electric vehicle is still expected to see exceptional growth over the next five years.
To help you take advantage of these benefits, we’ve created this special presentation that features seven stocks that appear ready to move on to the next leg.
Check out the “7 Electric Vehicle (EV) Inventories Ready To Recover”.
